Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NAOV Stock Summary
Top 10 Correlated ETFs
NAOV
In the News

What Is Going on With NanoVibronix (NAOV) Stock Today?
NanoVibronix (NASDAQ: NAOV ) stock is falling on Tuesday following news of a registered direct offering from the therapeutic ultrasound technology company. This direct offering has NanoVirbronix agreeing to sell 4.8 million shares of NAOV stock to several institutional investors.

Long Term Penny Stocks Investing Strategy (Complete Guide)
Use this guide for investing in penny stocks in the long term The post Long Term Penny Stocks Investing Strategy (Complete Guide) appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

NanoVibronix Sets Date for Annual Shareholder Meeting
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), announced today that its annual meeting of shareholders (the “Annual Meeting”) will take place at 10 a.m. Eastern time on December 15, 2022. The Company will hold the Annual Meeting virtually via the internet. The record date for determination of shareholders entitled to vote at the Annual Meeting is October 17, 2022. The Company anticipates sending proxy materials for the Annual Meeting to stockholders in Nove

Best Penny Stocks to Buy Now? Here's 3 to Watch in April 2022
Can these penny stocks continue to make moves next month? The post Best Penny Stocks to Buy Now?

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?

Health Canada Approves NanoVibronix's PainGuard, UroGuard As Licensed Devices
NanoVibronix Inc's (NASDAQ: NAOV) PainGuard and UroGuard have been approved by Health Canada / Santé Canada as licensed medical devices. The products are offered as private label products through Ideal Medical International Limited.

NanoVibronix, Medina Ink Distribution Pact For Ultrasound Devices In Europe
NanoVibronix Inc (NASDAQ: NAOV) has commenced sales in Europe by signing a distribution agreement with Medina Healthcare Ltd for UroShield and PainShield devices. UroShield is an ultrasound-based product designed to prevent bacterial colonization and biofilm on indwelling urinary catheters and increase antibiotic efficacy, ultimately reducing the incidence of catheter-associated urinary tract infections (CAUTI).

Top Penny Stocks to Know in Mid-October 2021? 3 to Watch
Are these penny stocks on your October watchlist? The post Top Penny Stocks to Know in Mid-October 2021?

NanoVibronix Shares Gain As PainShield Shows Effectiveness In Treating Soft Tissue Pain
NanoVibronix Inc (NASDAQ:NAOV) has announced results from a randomized, double-blind study to evaluate the safety and effectiveness of the NanoVibronix PainShield. Related: NanoVibronix Launches CBD-Based Product For Pain Management.

NAOV Stock: Why It Substantially Increased Today
The stock price of NanoVibronix, Inc., (NASDAQ: NAOV) increased by over 25% during intraday today. This is why it happened.
NAOV Financial details
NAOV Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.96 | 0.99 | 1.53 | 1.21 | 1.35 | |
Net income per share | -20 | -12.88 | -16.7 | -8.4 | -11.35 | |
Operating cash flow per share | -8.79 | -11.01 | -11.17 | -6.59 | -3.47 | |
Free cash flow per share | -8.79 | -11.04 | -11.17 | -6.59 | -3.47 | |
Cash per share | 17.57 | 2.78 | 3.86 | 13.87 | 6.15 | |
Book value per share | 14.64 | 1.44 | 3.89 | 4.65 | 5.02 | |
Tangible book value per share | 14.64 | 1.44 | 3.89 | 4.65 | 5.02 | |
Share holders equity per share | 14.64 | 1.44 | 3.89 | 4.65 | 5.02 | |
Interest debt per share | 4.97 | 0.07 | 0.18 | 0.35 | 0 | |
Market cap | 23.23M | 23.35M | 19.78M | 7.87M | 26.17M | |
Enterprise value | 18.87M | 22.45M | 18.44M | 757.79K | 18.48M | |
P/E ratio | -4.68 | -5.62 | -3.41 | -1.82 | -1.83 | |
Price to sales ratio | 97.2 | 73.43 | 37.32 | 12.63 | 15.44 | |
POCF ratio | -10.65 | -6.58 | -5.11 | -2.32 | -5.99 | |
PFCF ratio | -10.65 | -6.56 | -5.11 | -2.32 | -5.99 | |
P/B Ratio | 6.39 | 50.43 | 14.67 | 3.29 | 4.15 | |
PTB ratio | 6.39 | 50.43 | 14.67 | 3.29 | 4.15 | |
EV to sales | 78.96 | 70.61 | 34.79 | 1.22 | 10.9 | |
Enterprise value over EBITDA | -5.12 | -5.28 | -3.21 | -0.18 | -1.29 | |
EV to operating cash flow | -8.65 | -6.33 | -4.76 | -0.22 | -4.23 | |
EV to free cash flow | -8.65 | -6.31 | -4.76 | -0.22 | -4.23 | |
Earnings yield | -0.21 | -0.18 | -0.29 | -0.55 | -0.55 | |
Free cash flow yield | -0.09 | -0.15 | -0.2 | -0.43 | -0.17 | |
Debt to equity | 0.34 | 2.41 | 0.51 | 2.44 | 0.37 | |
Debt to assets | 0.25 | 0.71 | 0.34 | 0.71 | 0.27 | |
Net debt to EBITDA | 1.18 | 0.21 | 0.23 | 1.71 | 0.54 | |
Current ratio | 5.67 | 1.92 | 4.49 | 2.75 | 4.38 | |
Interest coverage | -2.5 | -195.59 | -83.08 | -32.1 | 118.4 | |
Income quality | 0.44 | 0.85 | 0.67 | 0.78 | 0.31 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 8.72 | 8.29 | 7.21 | 6.05 | 2.98 | |
Research and developement to revenue | 2.9 | 1.93 | 0.97 | 0.27 | 0.17 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.03 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -1.33 | 0 | -1 | -1.5 | |
Stock based compensation to revenue | 3.35 | 2.8 | 3.31 | 0.6 | 0.23 | |
Graham number | 81.18 | 20.4 | 38.21 | 29.64 | 35.8 | |
ROIC | 0.77 | 10.31 | 6.68 | 0.76 | 0.82 | |
Return on tangible assets | -1.02 | -2.63 | -2.85 | -0.53 | -1.66 | |
Graham Net | 12.87 | -0.13 | 2.33 | 2.81 | 4.54 | |
Working capital | 3.72M | 586K | 1.43M | 5.07M | 6.44M | |
Tangible asset value | 3.63M | 463K | 1.35M | 2.39M | 6.31M | |
Net current asset value | 3.29M | 109K | 1.15M | 2.14M | 6.03M | |
Invested capital | 0 | 0 | 0 | 0.01 | 0.01 | |
Average receivables | 24.5K | 89.5K | 137K | 111.5K | 178.5K | |
Average payables | 125K | 180.5K | 161K | 136.5K | 115.5K | |
Average inventory | 71.5K | 110K | 132.5K | 133K | 160K | |
Days sales outstanding | 53.45 | 165.28 | 89.53 | 54.49 | 56.85 | |
Days payables outstanding | 696.82 | 445.85 | 189.1 | 128.51 | 34.33 | |
Days of inventory on hand | 315.23 | 332.66 | 177.37 | 129.4 | 69.05 | |
Receivables turnover | 6.83 | 2.21 | 4.08 | 6.7 | 6.42 | |
Payables turnover | 0.52 | 0.82 | 1.93 | 2.84 | 10.63 | |
Inventory turnover | 1.16 | 1.1 | 2.06 | 2.82 | 5.29 | |
ROE | -1.37 | -8.97 | -4.3 | -1.81 | -2.26 | |
Capex per share | 0 | -0.02 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
---|---|---|---|---|---|---|
Revenue per share | 0.38 | 0.59 | 0.19 | 0.35 | 0.07 | |
Net income per share | -5.12 | -1.9 | -0.81 | -0.93 | -0.68 | |
Operating cash flow per share | -0.49 | -0.66 | -1.24 | -1.43 | -1.4 | |
Free cash flow per share | -0.49 | -0.66 | -1.24 | -1.43 | -1.4 | |
Cash per share | 6.59 | 5.93 | 4.28 | 2.82 | 1.41 | |
Book value per share | 6.68 | 4.84 | 3.76 | 2.95 | 2.25 | |
Tangible book value per share | 6.68 | 4.84 | 3.76 | 2.95 | 2.25 | |
Share holders equity per share | 6.68 | 4.84 | 3.76 | 2.95 | 2.25 | |
Interest debt per share | 0 | 0.02 | 0.02 | 0.02 | 0.03 | |
Market cap | 53.76M | 27.14M | 32.48M | 17.64M | 12.88M | |
Enterprise value | 45.18M | 19.45M | 26.53M | 13.73M | 10.93M | |
P/E ratio | -2.01 | -2.74 | -7.17 | -3.39 | -3.37 | |
Price to sales ratio | 107.73 | 35.02 | 119.4 | 36.37 | 132.77 | |
POCF ratio | -84.79 | -31.45 | -18.65 | -8.82 | -6.56 | |
PFCF ratio | -84.66 | -31.45 | -18.65 | -8.81 | -6.55 | |
P/B Ratio | 6.17 | 4.3 | 6.17 | 4.27 | 4.08 | |
PTB ratio | 6.17 | 4.3 | 6.17 | 4.27 | 4.08 | |
EV to sales | 90.54 | 25.1 | 97.54 | 28.3 | 112.73 | |
Enterprise value over EBITDA | -6.82 | -7.64 | -23.31 | -10.67 | -11.85 | |
EV to operating cash flow | -71.26 | -22.54 | -15.24 | -6.87 | -5.57 | |
EV to free cash flow | -71.15 | -22.54 | -15.24 | -6.86 | -5.56 | |
Earnings yield | -0.12 | -0.09 | -0.03 | -0.07 | -0.07 | |
Free cash flow yield | -0.01 | -0.03 | -0.05 | -0.11 | -0.15 | |
Debt to equity | 0.11 | 0.37 | 0.46 | 0.58 | 0.65 | |
Debt to assets | 0.1 | 0.27 | 0.31 | 0.37 | 0.39 | |
Net debt to EBITDA | 1.29 | 3.02 | 5.22 | 3.04 | 2.11 | |
Current ratio | 35.43 | 4.38 | 3.68 | 3.07 | 2.91 | |
Interest coverage | 37.74 | 132.11 | 85.54 | 0 | -57.75 | |
Income quality | 0.09 | 0.35 | 1.54 | 1.54 | 2.06 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.61 | 3.1 | 3.46 | 2.38 | 7.61 | |
Research and developement to revenue | 0.1 | 0.15 | 0.24 | 0.13 | 0.51 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.02 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -2 | |
Stock based compensation to revenue | -0.19 | 0.35 | 0.32 | 0.45 | -0.2 | |
Graham number | 27.72 | 14.37 | 8.27 | 7.86 | 5.88 | |
ROIC | 0.12 | 0.35 | 0.25 | 0.85 | -0.77 | |
Return on tangible assets | -0.69 | -0.29 | -0.15 | -0.2 | -0.18 | |
Graham Net | 6.29 | 4.38 | 3.25 | 2.2 | 1.28 | |
Working capital | 9.16M | 6.44M | 5.38M | 4.26M | 3.27M | |
Tangible asset value | 8.71M | 6.31M | 5.26M | 4.13M | 3.15M | |
Net current asset value | 8.47M | 6.03M | 4.99M | 3.9M | 2.93M | |
Invested capital | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 666K | 444.5K | 654.5K | 1.24M | 1.45M | |
Average payables | 121.5K | 74.5K | 129.5K | 172.5K | 107K | |
Average inventory | 203K | 188K | 265K | 641.5K | 1.24M | |
Days sales outstanding | 112.73 | 30.66 | 345.77 | 266.66 | 1.36K | |
Days payables outstanding | 20.59 | 15.12 | 93.25 | 76.32 | 217.06 | |
Days of inventory on hand | 66.75 | 30.41 | 192.47 | 409.41 | 8.22K | |
Receivables turnover | 0.8 | 2.94 | 0.26 | 0.34 | 0.07 | |
Payables turnover | 4.37 | 5.95 | 0.97 | 1.18 | 0.41 | |
Inventory turnover | 1.35 | 2.96 | 0.47 | 0.22 | 0.01 | |
ROE | -0.77 | -0.39 | -0.22 | -0.31 | -0.3 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
NAOV Frequently Asked Questions
What is NanoVibronix, Inc. stock symbol ?
NanoVibronix, Inc. is a US stock , located in Elmsford of Ny and trading under the symbol NAOV
What is NanoVibronix, Inc. stock quote today ?
NanoVibronix, Inc. stock price is $3.65 today.
Is NanoVibronix, Inc. stock public?
Yes, NanoVibronix, Inc. is a publicly traded company.